Worth reading
70In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
3
InstrumentWording
Definitive
How definitive the wording is.Announced details
Dapagliflozin OD Tablets 5 mg “Kyorin”Dapagliflozin OD Tablets 10 mg “Kyorin”Bilastine OD Tablets 20 mg “Kyorin”
Applicable field (uses covered by this announcement)
Type 2 diabetesAllergic rhinitisUrticariaPruritus associated with skin diseases (eczema, dermatitis and cutaneous pruritus)
Launch date12 June 2026 (scheduled for launch; the main text states that the launch is tomorrow)
Relationship between the counterparty and the company
KYORIN Pharmaceutical Co.,Ltd.4569
Relationship with the Company
Kyorin Rimedio Co., Ltd. is our subsidiary
Registration number and expiry date
GS1 DataBar：(01)14987060310696、(01)14987060310702、(01)14987060310719、(01)14987060310726
Offering price
Dapagliflozin OD Tablets 5 mg: NHI drug price ¥48.70 per tablet
Dapagliflozin OD Tablets 10 mg: NHI drug price ¥72.00 per tablet
Bilastine OD Tablets 20 mg: NHI drug price ¥17.70 per tablet
The company does not address Contract Value / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Dapagliflozin OD Tablets 5 mg “Kyorin”, Dapagliflozin OD Tablets 10 mg “Kyorin”, Bilastine OD Tablets 20 mg “Kyorin” |
| Relationship with the Company | Kyorin Rimedio Co., Ltd. is our subsidiary |
| Offering price | Dapagliflozin OD Tablets 5 mg: NHI drug price ¥48.70 per tablet, Dapagliflozin OD Tablets 10 mg: NHI drug price ¥72.00 per tablet, Bilastine OD Tablets 20 mg: NHI drug price ¥17.70 per tablet |
| Launch date | 12 June 2026 (scheduled for launch; the main text states that the launch is tomorrow) |
| Applicable area | Type 2 diabetes, Allergic rhinitis, Urticaria, Pruritus associated with skin diseases (eczema, dermatitis and cutaneous pruritus) |
| Registration number and expiry date | GS1 DataBar：(01)14987060310696、(01)14987060310702、(01)14987060310719、(01)14987060310726 |
Items this document does not state (12)
CounterpartyCounterparty overviewContract ValueContract DateAward/certification nameAwarding / certifying bodyLocationLocation scaleQuantitative EffectsUsage historyImpact on Business PerformanceSource
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Kyorin Rimedio Co., Ltd. will work to ensure a stable supply of its products and contribute to people's health through the sale of trusted generic drugs.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.